iSpecimen Inc.

ISPC Healthcare Diagnostics & Research

iSpecimen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 million, down 79.2% from fiscal 2024. In the quarter to June 2026, revenue fell 78.7%, EPS grew 94.2% and free cash flow fell 257.7%, each against the same quarter a year earlier.

0.92 0.11 −10.68%
Market cap
$2.6M
P/E
0.0×
Fwd P/E
−0.3×
Dividend yield
—
F-score
3/9
Altman Z
−14.80
Beneish M
10.08
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
3 3 3 2

+8 more TTM periods

ROE
(968.44%) (894.60%) (327.77%) (296.20%)
ROA
(170.09%) (165.08%) (111.09%) (113.84%)
ROIC
0.00% 0.00% 0.00% (2,615.23%)
Return on Tangible Assets
1,175.48% 530.64% (1,400.56%) 561.54%
Average Days of Receivables
16.67 47.17 9.14 13.16
Free Cash Flow per Share
(6.24) (24.04) (46.17) (55.65)
Free Cash Flow
(8.70) (8.21) (5.31) (8.12)
Other line items

Show all line items

Columns are period end dates